Cadrenal Therapeutics issues going-concern warning
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Cadrenal Therapeutics, Inc. (CVKD) reported a net loss of $7.1 million for the nine months ended September 30, 2026, compared with $10.2 million a year earlier; cash used in operations was $7.2 million. Cash and cash equivalents were $3.1 million at September 30, 2026, and accumulated deficit was $46.0 million. Cadrenal said its existing cash resources would not cover operating and capital needs for the next 12 months, raising substantial doubt about its ability to continue as a going concern for at least one year after the statements were issued.
On October 7, 2026, the board began a strategic review and retained Tungsten Advisors as its exclusive strategic financial advisor. Options include asset licensing or sales, partnerships, portfolio transactions, a business combination or reverse merger; no definitive transaction is assured. Cadrenal and the FDA aligned on key protocol and Statistical Analysis Plan aspects for a Phase 3 registrational study of CAD-1005 in HIT. Cadrenal said it has not raised enough to complete any clinical trial and will not commence one unless it believes it has sufficient funding to complete it. As of early November 2026, Cadrenal reported a cash position of $2.7 million and believed it could meet immediate operating needs through the first quarter of 2027.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Positive
- Moderate pointNine-month net loss declined 31% to $7.1 million year over year.
Negative
- Major pointGoing-concern substantial doubt extends at least one year.
Filing Explained
The 575,000-option grant creates potential dilution only if exercised; the options were not common shares issued by the grant.
Form 10-Q is the unaudited quarterly report on interim financial statements and updates to risks and liquidity. On
At
Key Figures
Key Terms
Type D meeting regulatory
Statistical Analysis Plan technical
12-LOX inhibitor medical
Orphan Drug designation regulatory
at-the-market (ATM) facility financial
going concern financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did CVKD report for the first nine months of 2026?
Does CVKD have enough cash to fund the next 12 months?
What is CVKD’s strategic review evaluating?
AI-generated analysis. How Rhea-AI works. Not financial advice.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
For the quarterly period ended
OR
For the transition period from to
Commission file number
(Exact name of registrant as specified in its charter)
| (State or other jurisdiction of incorporation or organization) |
(I.R.S. Employer Identification No.) |
| (Address of principal executive offices) | (Zip Code) |
Registrant’s telephone number, including area code:
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading symbol(s) | Name of each exchange on which registered | ||
(The Nasdaq Capital Market) |
Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act:
| Large accelerated filer | ☐ | Accelerated filer | ☐ |
| ☒ | Smaller reporting company | ||
| Emerging growth company |
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period to comply with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No
As of November 16, 2026, there were
CADRENAL THERAPEUTICS, INC.
QUARTERLY REPORT ON FORM 10-Q
FOR THE QUARTERLY PERIOD ENDED SEPTEMBER 30, 2026
TABLE OF CONTENTS
| Page | ||
| PART I. FINANCIAL INFORMATION | 1 | |
| Item 1. | Financial Statements (Unaudited) | 1 |
| Balance Sheets at September 30, 2026 and December 31, 2025 | 1 | |
| Statements of Operations and Comprehensive Loss for the Three and Nine Months Ended September 30, 2026 and 2025 | 2 | |
| Statements of Changes in Stockholders’ Equity for the Three and Nine Months Ended September 30, 2026 and 2025 | 3 | |
| Statements of Cash Flows for the Nine Months Ended September 30, 2026 and 2025 | 5 | |
| Notes to Financial Statements | 6 | |
| Item 2. | Management’s Discussion and Analysis of Financial Condition and Results of Operations | 21 |
| Item 3. | Quantitative and Qualitative Disclosures About Market Risk | 27 |
| Item 4. | Controls and Procedures | 27 |
| PART II. OTHER INFORMATION | 28 | |
| Item 1. | Legal Proceedings | 28 |
| Item 1A. | Risk Factors | 28 |
| Item 2. | Unregistered Sales of Equity Securities and Use of Proceeds | 32 |
| Item 3. | Defaults Upon Senior Securities | 33 |
| Item 4. | Mine Safety Disclosures | 33 |
| Item 5. | Other Information | 33 |
| Item 6. | Exhibits | 33 |
| SIGNATURES | 34 | |
i
PART I. FINANCIAL INFORMATION
Item 1. Financial Statements (Unaudited)
CADRENAL THERAPEUTICS, INC.
BALANCE SHEETS
| September 30, 2026 |
December 31, | |||||||
| (unaudited) | 2025 | |||||||
| Assets: | ||||||||
| Current assets: | ||||||||
| Cash and cash equivalents | $ | $ | ||||||
| Interest receivable | ||||||||
| Prepaid expenses and other current assets | ||||||||
| Deferred offering costs | ||||||||
| Total current assets | ||||||||
| Property, plant and equipment, net | ||||||||
| Other assets | ||||||||
| Total assets | $ | $ | ||||||
| Liabilities and Stockholders’ Equity: | ||||||||
| Current liabilities: | ||||||||
| Accounts payable | $ | $ | ||||||
| Accrued liabilities | ||||||||
| Total current liabilities | ||||||||
| Total liabilities | ||||||||
| Stockholders’ equity: | ||||||||
| Preferred stock, $ issued and outstanding as of September 30, 2026 and December 31, 2025 | - | - | ||||||
| Common stock, $ | ||||||||
| Additional paid-in capital | ||||||||
| Accumulated deficit | ( | ) | ( | ) | ||||
| Total stockholders’ equity | ||||||||
| Total liabilities and stockholders’ equity | $ | $ | ||||||
The accompanying notes are an integral part of these financial statements.
1
CADRENAL THERAPEUTICS, INC.
STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS
(unaudited)
| Three Months Ended September 30, |
Nine Months Ended September 30, |
|||||||||||||||
| 2026 | 2025 | 2026 | 2025 | |||||||||||||
| Operating expenses: | ||||||||||||||||
| General and administrative expenses | $ | $ | $ | $ | ||||||||||||
| Research and development expenses | ||||||||||||||||
| Depreciation expense | ||||||||||||||||
| Total operating expenses | ||||||||||||||||
| Loss from operations | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||
| Other income | ||||||||||||||||
| Interest and dividend income | ||||||||||||||||
| Total other income | ||||||||||||||||
| Net loss and comprehensive loss | $ | ( | ) | $ | ( | ) | $ | ( | ) | $ | ( | ) | ||||
| Net loss per common share, basic and diluted | $ | ( | ) | $ | ( | ) | $ | ( | ) | $ | ( | ) | ||||
| Weighted average number of common shares used in computing net loss per common share, basic and diluted | ||||||||||||||||
The accompanying notes are an integral part of these financial statements.
2
CADRENAL THERAPEUTICS, INC.
STATEMENTS OF CHANGES IN STOCKHOLDERS’ EQUITY
(unaudited)
| Three Months Ended September 30, 2026 | ||||||||||||||||||||
| Common Stock | Additional Paid-In |
Accumulated | Total Stockholders’ |
|||||||||||||||||
| Shares | Amount | Capital | Deficit | Equity | ||||||||||||||||
| Balance, June 30, 2026 | $ | $ | $ | ( | ) | $ | ||||||||||||||
| Equity-based compensation - options | - | - | - | |||||||||||||||||
| Issuance costs from warrant inducements | - | - | ( | ) | - | ( | ) | |||||||||||||
| Proceeds from pre-funded warrant exercise | ( | ) | ||||||||||||||||||
| Issuance costs from warrant issuances | - | - | ( | ) | - | ( | ) | |||||||||||||
| Net loss | - | - | - | ( | ) | ( | ) | |||||||||||||
| Balance, September 30, 2026 | $ | $ | $ | ( | ) | $ | ||||||||||||||
| Nine Months Ended September 30, 2026 | ||||||||||||||||||||
| Common Stock | Additional Paid-In |
Accumulated | Total Stockholders’ |
|||||||||||||||||
| Shares | Amount | Capital | Deficit | Equity | ||||||||||||||||
| Balance, December 31, 2025 | $ | $ | $ | ( | ) | $ | ||||||||||||||
| Equity-based compensation - options | - | - | - | |||||||||||||||||
| Proceeds from sale of common stock under the ATM, net of issuance costs of $ | - | |||||||||||||||||||
| Proceeds from warrant inducements, net of issuance costs of $ | - | |||||||||||||||||||
| Proceeds from pre-funded warrant exercise | ( | ) | ||||||||||||||||||
| Proceeds from warrant issuances, net of issuance costs of $ | - | - | - | |||||||||||||||||
| Net loss | - | - | - | ( | ) | ( | ) | |||||||||||||
| Balance, September 30, 2026 | $ | $ | $ | ( | ) | $ | ||||||||||||||
The accompanying notes are an integral part of these financial statements.
3
CADRENAL THERAPEUTICS, INC.
STATEMENTS OF CHANGES IN STOCKHOLDERS’ EQUITY (CONTINUED)
(unaudited)
| Three Months Ended September 30, 2025 | ||||||||||||||||||||
| Common Stock | Additional Paid-In |
Accumulated | Total Stockholders’ |
|||||||||||||||||
| Shares | Amount | Capital | Deficit | Equity | ||||||||||||||||
| Balance, June 30, 2025 | $ | $ | $ | ( | ) | $ | ||||||||||||||
| Equity-based compensation - options | - | - | - | |||||||||||||||||
| Proceeds from sale of common stock, net issuance costs of $ | - | |||||||||||||||||||
| Exercise of stock options | - | |||||||||||||||||||
| Net loss | - | - | - | ( | ) | ( | ) | |||||||||||||
| Balance, September 30, 2025 | $ | $ | $ | ( | ) | $ | ||||||||||||||
| Nine Months Ended September 30, 2025 | ||||||||||||||||||||
| Common Stock | Additional Paid-In |
Accumulated | Total Stockholders’ |
|||||||||||||||||
| Shares | Amount | Capital | Deficit | Equity | ||||||||||||||||
| Balance, December 31, 2024 | $ | $ | $ | ( | ) | $ | ||||||||||||||
| Equity-based compensation - options | - | - | - | |||||||||||||||||
| Issuance of common stock for consulting services | - | |||||||||||||||||||
| Proceeds from sale of common stock, net issuance costs of $ | - | |||||||||||||||||||
| Exercise of stock options | ||||||||||||||||||||
| Net loss | - | - | - | ( | ) | ( | ) | |||||||||||||
| Balance, September 30, 2025 | $ | $ | $ | ( | ) | $ | ||||||||||||||
The accompanying notes are an integral part of these financial statements.
4
CADRENAL THERAPEUTICS, INC.
STATEMENTS OF CASH FLOWS
(unaudited)
| Nine Months Ended September 30, |
||||||||
| 2026 | 2025 | |||||||
| Cash flows used in operating activities: | ||||||||
| Net loss | $ | ( | ) | $ | ( | ) | ||
| Adjustments to reconcile net loss to net cash used in operating activities: | ||||||||
| Depreciation expense | ||||||||
| Equity-based compensation | ||||||||
| Loss on disposal of property & equipment | - | |||||||
| Changes in operating assets and liabilities: | ||||||||
| Interest receivable | ( | ) | ||||||
| Prepaid expenses | ( | ) | ( | ) | ||||
| Deferred offering costs | ( | ) | ||||||
| Other assets | - | |||||||
| Accounts payable | ( | ) | ( | ) | ||||
| Accrued liabilities | ( | ) | ( | ) | ||||
| Net cash used in operating activities | ( | ) | ( | ) | ||||
| Cash flows from investing activities: | ||||||||
| Investment in property and equipment | - | ( | ) | |||||
| Net cash used in investing activities | - | ( | ) | |||||
| Cash flows from financing activities: | ||||||||
| Proceeds from warrant inducements | - | |||||||
| Issuance costs from warrant inducement | ( | ) | - | |||||
| Proceeds from sale of common stock under ATM | ||||||||
| Issuance costs for sale of common stock under ATM | ( | ) | ( | ) | ||||
| Proceeds from warrant issuance | - | |||||||
| Issuance costs from warrant issuance | ( | ) | - | |||||
| Proceeds from exercise of pre-funded warrants | - | |||||||
| Proceeds from exercise of stock options | - | |||||||
| Net cash provided by financing activities | ||||||||
| Net change in cash and cash equivalents | ( | ) | ( | ) | ||||
| Cash and cash equivalents – beginning of the period | ||||||||
| Cash and cash equivalents – end of the period | $ | $ | ||||||
The accompanying notes are an integral part of these financial statements.
5
CADRENAL THERAPEUTICS, INC.
Notes to Financial Statements
(unaudited)
Note 1. Description of Business and Summary of Significant Accounting Policies
Cadrenal Therapeutics, Inc. (the “Company” or “Cadrenal”) was incorporated on
The Company’s broader pipeline includes tecarfarin, a late-stage oral vitamin K antagonist being designed to prevent heart attacks, strokes, and deaths from blood clots in patients requiring chronic anticoagulation, including those with end-stage kidney disease, those with left ventricular assist devices, and potentially those with Kawasaki disease (KD), an acute, self-limited, febrile illness that primarily affects children under 5 years old and is the leading cause of acquired heart disease in developed countries. Tecarfarin has also received Orphan Drug and Fast Track designations from the U.S. Food and Drug Administration (FDA). The Company has also applied for a rare pediatric disease designation (RPDD) for tecarfarin. On October 22, 2026, the Company submitted a formal amendment to its RPDD request to the FDA, refining the proposed indication strictly to the prevention of acute myocardial infarction and luminal occlusion in pediatric patients with Chronic Kawasaki Disease-Induced Giant Coronary Artery Aneurysms (defined by a localized Z-score ≥10 or absolute internal diameter ≥8 mm).
Basis of Presentation
The accompanying financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) and applicable rules and regulations of the U.S. Securities and Exchange Commission (“SEC”) for the fair presentation of the Company’s financial statements for the periods presented. The Company’s fiscal year-end is December 31.
The Company’s accompanying financial statements are unaudited. The unaudited interim financial statements have been prepared on the same basis as the audited annual financial statements and, in the opinion of management, reflect all adjustments, which include only normal recurring adjustments, necessary for the fair statement of the Company’s financial position as of September 30, 2026, the results of its operations for the three and nine months ended September 30, 2026 and 2025, the statements of changes in stockholders’ equity for the three and nine months ended September 30, 2026 and 2025, and its cash flows for the nine months ended September 30, 2026 and 2025. The financial data and other information disclosed in these notes related to the three and nine months ended September 30, 2026 and 2025 are also unaudited. The results for the three and nine months ended September 30, 2026, are not necessarily indicative of results to be expected for the year ending December 31, 2026, any other interim periods, or any future year or period. These interim financial statements should be read in conjunction with the audited financial statements as of and for the year ended December 31, 2025, and notes thereto, which are included in the Company’s Annual Report on Form 10-K filed with the SEC on March 31, 2026.
Liquidity
The accompanying financial statements have been prepared on the assumption that the Company will continue as a going concern, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of business. The financial statements do not reflect any adjustments relating to the recoverability and reclassification of assets and liabilities that might be necessary if the Company is unable to continue as a going concern. Since its inception, the Company has incurred operating losses and negative cash flows from operations. For the nine months ended September 30, 2026, the Company had a net loss of $
6
The Company is projecting that its operating losses and expected capital needs will exceed its existing cash balances and cash expected to be generated from operations for the foreseeable future. In order to meet the Company’s expected capital needs, management is focusing on securing additional funds through partnering, non-dilutive grants, the sale of equity, and debt financings. However, there can be no assurance that the Company will be able to complete partnering transactions or financings on terms acceptable to the Company or at all or that it will be awarded any grant funding. To date, the Company has not been successful in raising sufficient funds to allow it to complete any clinical trials and the Company will not commence a trial that it does not believe it has sufficient funding to complete. On October 7, 2026, the Company announced that its Board of Directors has initiated a formal strategic process to evaluate opportunities to maximize the value of the Company and its assets. Potential opportunities may include licensing or sale of individual assets, development and commercialization partnerships, portfolio transactions, business combinations, reverse merger or other strategic transactions.
As a result, there is uncertainty as to the Company’s ability to meet its current operating and capital expenses. These factors, among others, raise substantial doubt about the Company’s ability to continue as a going concern for at least one year from the date the accompanying financial statements are issued. If the Company is unable to monetize its assets or obtain additional funding, it will be required to delay, scale back or discontinue development programs, liquidate intellectual property or other assets, or cease operations entirely. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.
Emerging Growth Company Status
As an “emerging growth company” (“EGC”) under the Jumpstart Our Business Startups Act (“JOBS Act”), the Company may elect to take advantage of certain forms of relief from various reporting requirements that apply to public companies. The relief under the JOBS Act includes an extended transition period for implementing new or revised accounting standards. The Company has elected to take advantage of this extended transition period and, as a result, the Company’s financial statements may not be comparable to those of companies that implement accounting standards as of the effective dates for public companies. The Company may take advantage of the relief afforded under the JOBS Act up until the last day of the fiscal year following the fifth anniversary of an offering or such earlier time that it is no longer an EGC.
Use of Estimates
Preparing financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of expenses during the reporting period. Significant estimates and assumptions made in the accompanying financial statements include, but are not limited to, the fair value of stock-based awards, deferred tax assets and valuation allowance, income tax uncertainties, and certain accruals. The Company evaluates its estimates and assumptions on an ongoing basis using historical experience and other factors and adjusts those estimates and assumptions when facts and circumstances change. Actual results could differ from those estimates.
Concentration of Credit and Other Risks and Uncertainties
Financial instruments, which potentially subject the Company to significant concentrations of credit risk, consist primarily of cash and cash equivalents. The Company maintains cash at high-credit-quality financial institutions; at times, balances may exceed federally insured limits. All interest-bearing and non-interest-bearing cash balances are insured up to $
The Company is subject to several risks common for late-stage biopharmaceutical companies including, but not limited to, dependency on the clinical and commercial success of its product candidates, ability to obtain regulatory approval of its product candidate, the need for substantial additional financing to achieve its goals, uncertainty of broad adoption of its approved products, if any, by physicians and patients, significant competition and untested manufacturing capabilities.
7
Segment Reporting
Operating segments are defined as components of an entity where separate financial information is evaluated regularly by the chief operating decision maker (“CODM”) in deciding how to allocate resources and assess performance. The Company’s CODM is the Chief Executive Officer, who reviews company-wide financial information to allocate resources and assess financial performance. The Company manages its business activities as a single entity and operates in
Significant expenses within loss from operations and net loss include research and development and general and administrative expenses, which are each separately presented on the Company’s statements of operations and comprehensive loss. Other segment items include depreciation expense and interest and dividend income as presented on the Company’s statements of operations and comprehensive loss. The accounting policies used to measure the segment’s profit and loss are the same as those described in the summary of significant accounting policies.
The measure of segment assets is reported on the balance sheets as total assets.
Cash and Cash Equivalents
The Company considers all highly liquid investments purchased with original maturities of three months or less from the purchase date to be cash equivalents. Cash and cash equivalents include cash and money market funds.
Stock-Based Compensation
The Company measures its stock-based awards granted to employees, consultants, and directors based on the estimated grant-date fair values of the awards and recognizes the compensation over the requisite service period using the straight-line method. The Company uses the Black-Scholes option-pricing model to estimate the fair value of its stock option awards. The Company accounts for forfeitures as they occur.
The Black-Scholes model requires highly subjective and complex assumptions to determine the fair value of stock-based payment awards, including the option’s expected term and the price volatility of the underlying stock. The Company estimates the fair value of options granted by using the Black-Scholes model with the following assumptions:
| ● | Expected Volatility—The Company estimated volatility for option grants by evaluating the historical volatility of a peer group of companies for the period immediately preceding the option grant for a term that is approximately equal to the options’ expected term. |
| ● | Expected Term—The expected term of the Company’s options represents the period that the stock-based payment awards are expected to be outstanding. The expected term was estimated using the simplified method for employee stock options since the Company does not have adequate historical exercise data to estimate the expected term. |
| ● | Risk-Free Interest Rate — The Company bases the risk-free interest rate on the implied yield currently available on U.S. Treasury securities with maturities consistent with the expected term of the stock option awards. |
Deferred Offering Costs
The Company capitalizes certain legal, professional, and other third-party costs that are directly associated with in-process equity financings until such financings are consummated, at which time such costs are recorded against the gross proceeds of the offering. Should an in-process equity financing be abandoned, the deferred offering costs will be expensed immediately as a charge to operating expenses in the statements of operations and comprehensive loss.
8
Acquisitions
The Company evaluates acquisitions of assets and other similar transactions to assess whether or not the transaction should be accounted for as a business combination or asset acquisition by first applying a screen test to determine whether substantially all of the fair value of the gross assets acquired is concentrated in a single identifiable asset or group of similar identifiable assets. If so, the transaction is accounted for as an asset acquisition. If not, further determination is required as to whether or not the Company has acquired inputs and processes that have the ability to create outputs, which would meet the definition of a business. Significant judgment is required in applying the screen test to determine whether an acquisition is a business combination or an acquisition of assets.
Acquisitions that meet the definition of a business combination are accounted for under the acquisition method, which requires allocating the purchase price to the net assets acquired at their respective fair values. In a business combination, any excess of the purchase price over the estimated fair values of the net assets acquired is recorded as goodwill.
For asset acquisitions, the Company uses a cost-accumulation model to determine the cost of an asset acquisition. Direct transaction costs are recognized as part of the cost of an asset acquisition. The Company also evaluates which elements of a transaction should be accounted for as a part of an asset acquisition and which should be accounted for separately. The cost of an asset acquisition, including transaction costs, is allocated to identifiable assets acquired and liabilities assumed based on a relative fair value basis. Goodwill is not recognized in an asset acquisition. Any difference between the cost of an asset acquisition and the fair value of the net assets acquired is allocated to the non-monetary identifiable assets based on their relative fair values. When a transaction accounted for as an asset acquisition includes an in-process research and development (“IPR&D”) asset, the IPR&D asset is only capitalized if it has an alternative future use other than in a particular research and development project. For an IPR&D asset to have an alternative future use: (a) the Company must reasonably expect that it will use the asset acquired in an alternative manner and anticipate economic benefit from that alternative use, and (b) the Company’s use of the asset acquired is not contingent on the further development of the asset subsequent to the acquisition date (that is, the asset can be used in an alternative manner in the condition in which it existed at the acquisition date). Otherwise, amounts allocated to IPR&D that have no alternative use are expensed to research and development. Asset acquisitions may include contingent consideration arrangements that encompass obligations to make future payments to sellers contingent upon the achievement of future financial targets. Contingent consideration is not recognized until all contingencies are resolved and the consideration is paid or probable of payment, at which point the consideration is allocated to the assets acquired on a relative fair value basis.
Income Taxes
Income taxes are accounted for under the asset-and-liability method. Under this method, deferred tax assets and liabilities are determined based on the difference between the financial statement and tax bases of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to affect taxable income. Management assesses the likelihood that the resulting deferred tax assets will be realized. A valuation allowance is provided when it is more likely than not that some portion or all of a deferred tax asset will not be realized. Due to the Company’s historical operating performance and net losses, the net deferred tax assets have been fully offset by a valuation allowance.
The Company recognizes uncertain income tax positions at the largest amount, that is more likely than not to be sustained upon audit by the relevant taxing authority. An uncertain income tax position will not be recognized if it has less than a
9
Net Loss Per Common Share
Basic net loss per common share is calculated by dividing the net loss by the weighted-average number of shares of the Company’s common stock, par value $
Comprehensive Loss
Comprehensive loss is defined as the change in equity during a period from transactions and other events or circumstances from non-owner sources. Net loss and comprehensive loss were the same for the periods presented in the accompanying financial statements.
Research and Development Expenses
Research and development costs are expensed as incurred and consist of fees paid to other entities that conduct certain research and development activities on the Company’s behalf. Acquired intangible assets are expensed as research and development costs if, at the time of payment, the technology is under development; is not approved by the FDA or other regulatory agencies for marketing; has not reached technical feasibility; or otherwise has no foreseeable alternative future use. Non-refundable advance payments for goods or services to be received in the future for use in research and development activities are capitalized and then expensed as the related goods are delivered or the services are performed.
Patents
Patent costs are comprised primarily of external legal fees, filing fees incurred to file patent applications, and periodic renewal fees to keep the patent in force. They are expensed as incurred as a component of general and administrative expenses.
Note 2. Recent Accounting Pronouncements
Accounting Pronouncements Not Yet Adopted
In November 2024, the FASB issued ASU 2024-03, Income Statement – Reporting Comprehensive Income – Expense Disaggregation Disclosures (Subtopic 220-40). The ASU aims to improve financial reporting by requiring that public business entities disclose additional information about specific expense categories in the notes to financial statements at interim and annual reporting periods. In January 2025, the ASU was subsequently amended by ASU 2025-01 to clarify the effective date by which all public business entities are required to adopt the guidance in annual reporting periods beginning after December 15, 2026, and interim periods within annual reporting periods beginning after December 15, 2027. Early adoption of ASU 2024-03 is permitted. The Company is currently evaluating the impact of this guidance on its financial statements.
In December 2025, the FASB issued ASU 2025-11, Interim Reporting (Topic 270): Narrow-Scope Improvements, which clarifies the scope, form and content, and disclosures required for interim financial reporting. For public business entities, the amendments are effective for interim reporting periods within annual reporting periods beginning after December 15, 2027. Early adoption is permitted. The Company is currently evaluating the impact of this ASU on its interim financial statement disclosures.
In December 2025, the FASB issued ASU 2025-12, Codification Improvements, which includes amendments intended to clarify and improve various aspects of existing accounting guidance across multiple topics under U.S. GAAP. The amendments are effective for all entities for annual reporting periods beginning after December 15, 2026. Early adoption is permitted. The Company is currently evaluating the impact of ASU 2025-12 on its financial statements and disclosures.
10
Note 3. Fair Value Measurements
Assets and liabilities recorded at fair value on a recurring basis in the balance sheets are categorized based upon the level of judgment associated with the inputs used to measure their fair values. Fair value is defined as the exchange price that would be received for an asset or an exit price that would be paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. The authoritative guidance on fair value measurements establishes a three-tier fair value hierarchy for disclosure of fair value measurements as follows:
| ● | Level 1 — | Observable inputs such as unadjusted, quoted prices in active markets for identical assets or liabilities at the measurement date. | |
| ● | Level 2 — | Inputs (other than quoted prices included in Level 1) are either directly or indirectly observable for the asset or liability. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active. | |
| ● | Level 3 — | Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. |
Financial assets and liabilities subject to fair value measurements on a recurring basis, and the level of inputs used in such measurements by major security type are presented in the following tables:
| September 30, 2026 | ||||||||||||||||
| Level 1 | Level 2 | Level 3 | Fair Value | |||||||||||||
| Financial Assets: | ||||||||||||||||
| Money market funds | $ | $ | - | $ | - | $ | ||||||||||
| Total financial assets | $ | $ | - | $ | - | $ | ||||||||||
| December 31, 2025 | ||||||||||||||||
| Level 1 | Level 2 | Level 3 | Fair Value | |||||||||||||
| Financial Assets: | ||||||||||||||||
| Money market funds | $ | $ | - | $ | - | $ | ||||||||||
| Total financial assets | $ | $ | - | $ | - | $ | ||||||||||
The carrying amounts of cash and cash equivalents, prepaid expenses, deferred offering costs, accounts payable, and accrued liabilities approximate their fair values due to their short-term nature. There were no transfers of liabilities among the fair value measurement categories during any of the periods presented.
Note 4. Accrued Liabilities
Accrued liabilities consist of the following:
| September 30, 2026 | December 31, 2025 | |||||||
| Accrued compensation | $ | $ | ||||||
| Accrued research and development | ||||||||
| Accrued professional fees | - | |||||||
| Other | - | |||||||
| Total accrued liabilities | $ | $ | ||||||
11
Note 5. Asset Purchase Agreement
eXIthera Pharmaceuticals, Inc.
On September 12, 2025, the Company entered into an Asset Purchase Agreement (the “eXIthera APA”) with eXIthera Pharmaceuticals (“eXIthera”). Pursuant to the terms of the eXIthera APA, the Company acquired all of the rights, title and interests in assets owned or held for use by it in connection with the compounds known as frunexian (EP-7041) and EP-7327 and certain other compounds including all intellectual property, regulatory filings, clinical and non-clinical data, market analyses, commercialization plans, all inventory related to the compounds and other rights. In addition, the Company acquired the exclusive license agreement (the “Haisco License Agreement”) with Sichuan Haisco Pharmaceutical Co., Ltd. (“Haisco”), which relates to the development and commercialization of frunexian in the People’s Republic of China. In consideration of the purchase of the assets, the Company paid $
| Development Milestones | Milestone payment | |||
| First Patient Dosed in Phase 2 Initiated with Frunexian or EP-7327 | $ | |||
| First Patient Dosed in Phase 1 Initiated with EP-7327 | $ | |||
| First Patient Dosed in Phase 3 Initiated with Frunexian or EP-7327 | $ | |||
| FDA Approval of New Drug Application for Frunexian or EP-7327 | $ | |||
As additional consideration, the Company agreed to pay eXIthera royalties equal to
The Company accounted for the transaction as an asset acquisition because substantially all of the estimated fair value of the gross assets acquired was concentrated in a single identified in-process research and development asset, the frunexian asset, thus satisfying the requirements of the screen test under ASC 805-10-55-5C. The assets acquired in the transaction were measured based at the fair value of the consideration paid of $
| In-process research and development | $ | |||
| Transaction costs | ||||
| Total | $ |
All costs the Company incurred in connection with the eXIthera APA were recognized as research and development expenses in the Company’s statements of operations and comprehensive loss as these assets had no alternative future use at the time of the acquisition transaction. Because the contingent consideration depends on development, regulatory, and sales milestones, it was not included in the initial cost of the assets purchased, as it depends on events outside the Company’s control.
However, upon achievement or anticipated achievement of each milestone, the Company will recognize the related appropriate payment as additional research and development expense. Contingent consideration will not be recorded until it is probable that the milestone events will occur. As of September 30, 2026 and December 31, 2025, the milestones are not deemed probable, and therefore, no liability has been recognized.
12
Veralox Therapeutics Inc.
On December 10, 2025, the Company entered into an Asset Purchase Agreement (the “Veralox APA”) with Veralox Therapeutics, Inc. (“Veralox”). Pursuant to the terms of the Veralox APA, the Company acquired all of the rights, title and interests in assets owned or held for use by it in connection with the compound known as CAD-1005 (“CAD-1005”), and all back-up and follow-on compounds, including the CAD-2000 series (the “Compounds”), including, without limitation, all intellectual property related to the Compounds, all inventory related to the Compounds, certain contracts including a license agreement, all Permits and other Governmental Authorizations and Books and Records (as such terms are defined in the Veralox APA), free and clear of any liens. In consideration of the purchase of the assets, the Company paid $
| Development Milestones | Milestone payment | |||
| First Patient Dosed in the First Clinical Trial with CAD-1005 | $ | |||
| First regulatory filing approval to market a pharmaceutical product for human use containing a Compound that is covered by a patent owned or licensed by Veralox (the “Product”) in the United States | $ | |||
| First regulatory filing approval to market a Product outside the United States | $ | |||
| Regulatory filing approval to market a Product for a subsequent indication in the United States | $ | |||
| Regulatory filing approval to market a Product for a subsequent indication outside the United States | $ | |||
As additional consideration, the Company agreed to pay Veralox royalties equal to
The Company accounted for the transaction as an asset acquisition as substantially all of the estimated fair value of the gross assets acquired was concentrated in a single identified in-process research and development asset, the CAD-1005 compound asset, thus satisfying the requirements of the screen test in accordance with the criteria under ASC 805-10-55-5C. The Company measured assets at the fair value of the consideration paid of $
| In-process research and development | $ | |||
| Transaction costs | ||||
| Total | $ |
All costs the Company incurred in connection with the Veralox APA were recognized as research and development expenses in the Company’s statements of operations and comprehensive loss as these assets had no alternative future use at the time they were acquired. Because the consideration depends on development, regulatory, and sales milestones, the Company did not include contingent consideration in the initial cost of the assets, as it depends on events outside the Company’s control.
However, upon achievement or anticipated achievement of each milestone, the Company will recognize the related appropriate payment as additional research and development expense. Contingent consideration will not be recorded until it is probable that the milestone events will occur.
In addition, the Company acquired the assignment of an amended and restated exclusive license agreement (the “Old Dominion License Agreement”) between Veralox and Old Dominion University, as successor in interest to Eastern Virginia Medical School (the “Licensor”), pursuant to which the Licensor granted Veralox an exclusive worldwide license under the EVMS Patent Rights (as such term is defined in the Old Dominion License Agreement) related to the development and commercialization of 4-((2-Hydroxy-3-MethoxyBenzyl)Amino) Benzenesulfonamide Derivatives as 12-LOX Inhibitors (collectively the “Assets”). Pursuant to the Old Dominion License Agreement, the Company will pay Licensor milestone payments in the aggregate amount of $
13
Note 6. Stockholders’ Equity
Common Stock
The Company is authorized to issue a total of
Holders of Common Stock are entitled to
June 2026 Warrant Issuance
On June 30, 2026, the Company entered into a securities purchase agreement (the “Purchase Agreement”) with an investor, pursuant to which the Company issued and sold, in a private placement priced at-the-market under the rules of the Nasdaq Stock Market (the “PIPE Transaction”), (i) pre-funded warrants (the “Pre-Funded Warrants”) to purchase up to an aggregate of
The Pre-Funded Warrants have an exercise price of $
The Company received aggregate gross proceeds of approximately $
The Company utilized H.C. Wainwright & Co., LLC (“H.C.W.”) as exclusive placement agent for the PIPE Transaction and as partial compensation, the Company issued to designees of H.C.W. unregistered warrants (the “June 2026 Placement Agent Warrants”) to purchase up to an aggregate of
14
The Pre-Funded Warrants, Common Warrants, and 2026 Placement Agent Warrants were classified as equity, and the related offering costs were recorded as a debit to additional paid-in capital.
The Pre-Funded Warrants, Common Warrants, and 2026 Placement Agent Warrants contain customary provisions for adjustment to the exercise price for stock splits and stock dividends and provide for pro rata distributions.
During the three months ended September 30, 2026, a holder exercised Pre-Funded Warrants to purchase
April 2026 Warrant Inducement
On March 31, 2026, the Company entered into a warrant inducement letter agreement (the “Inducement Agreement”) with a holder of the Company’s outstanding warrants to purchase shares of the Common Stock, issued in a private placement offering that closed on November 4, 2024 (the “Existing Warrants”). Pursuant to the Inducement Agreement, the holder of the Existing Warrants agreed to exercise for cash the Existing Warrants to purchase an aggregate of
In consideration of the holder’s agreement to exercise the Existing Warrants at the reduced exercise price per share in accordance with the Inducement Agreement, the Company issued to the holder new unregistered Series B-1 Common Stock warrants (the “Series B-1 Warrants”) to purchase up to
On April 1, 2026, the transactions contemplated by the Inducement Agreement closed and the Company received aggregate gross proceeds of approximately $
H.C.W. acted as an exclusive placement agent for the transactions contemplated by the Inducement Agreement and issued to the placement agent as partial compensation unregistered warrants to purchase up to
The New Warrants, and April 2026 Placement Agent Warrants were classified as equity, and the offering costs were recorded as debit to additional paid-in capital.
The New Warrants and April 2026 Placement Agent Warrants provide that the holder thereof has the right to participate in distributions or dividends paid on the Company’s shares of Common Stock on an as-converted basis.
15
2025 Direct Registered Offering
On December 15, 2025, the Company entered into a securities purchase agreement with certain investors. The agreement provided for the sale and issuance by the Company of an aggregate of (i) in a registered direct offering,
The offering price was $
The 2025 Common Warrants have an exercise price of $
H.C.W acted as the placement agent for the Company in connection with the December 2025 Offering, and as part of its compensation, the Company issued to designees of H.C.W. placement agent warrants (the “December 2025Placement Agent Warrants”) to purchase up to
The 2025 Common Warrants and December 2025 Placement Agent Warrants were classified as equity, and the offering costs were recorded as a debit to additional paid-in capital.
ATM Facility
During the nine months ended September 30, 2026, the Company sold
16
Warrant Summary
The following table summarizes the total warrants outstanding at September 30, 2026, all of which are classified as equity:
| Outstanding | Outstanding | |||||||||||||||||||||||||||
| Exercise | as of | as of | ||||||||||||||||||||||||||
| Price | Expiration | December 31, | New | September 30, | ||||||||||||||||||||||||
| Issue Date | Per Share | Date | 2025 | Issuance | Exercised | 2026 | ||||||||||||||||||||||
| Placement agent warrants | $ | - | - | |||||||||||||||||||||||||
| Placement agent warrants | $ | - | - | |||||||||||||||||||||||||
| Representative warrants | $ | - | - | |||||||||||||||||||||||||
| Placement agent warrants | $ | - | - | |||||||||||||||||||||||||
| New Series A-1 warrants | $ | - | ( | ) | - | |||||||||||||||||||||||
| New Series A-2 warrants | $ | - | ( | ) | - | |||||||||||||||||||||||
| Placement agent warrants | $ | - | - | |||||||||||||||||||||||||
| Investor Warrants 2025 | $ | - | - | |||||||||||||||||||||||||
| Placement agent warrants | $ | - | - | |||||||||||||||||||||||||
| New Series B-1 warrants | $ | - | - | |||||||||||||||||||||||||
| New Series B-2 warrants | $ | - | - | |||||||||||||||||||||||||
| Placement agent warrants | $ | - | - | |||||||||||||||||||||||||
| Pre-funded warrants | $ | - | ( | ) | - | |||||||||||||||||||||||
| New Series C-1 warrants | $ | - | - | |||||||||||||||||||||||||
| New Series C-2 warrants | $ | - | - | |||||||||||||||||||||||||
| Placement agent warrants | $ | - | - | |||||||||||||||||||||||||
| ( | ) | |||||||||||||||||||||||||||
Note 7. Equity-Based Compensation
The Company adopted the Cadrenal Therapeutics, Inc. 2022 Equity Incentive Plan (the “Initial Plan”), on July 11, 2022, which was later amended and restated on October 16, 2022. On October 16, 2022, the Board adopted and the Company’s stockholders approved the Cadrenal Therapeutics, Inc. 2022 Successor Equity Incentive Plan (the “2022 Plan”), which is a successor to and continuation of the Initial Plan and became effective on January 19, 2023. The Initial Plan and the 2022 Plan are collectively referred to as the “Plans.”
The maximum number of shares of Common Stock that may be issued under the 2022 Plan automatically increase on January 1 of each calendar year for a period of
17
There were no options granted during the nine months ended September 30, 2026.
| Nine Months Ended September 30, 2026 | Nine Months Ended September 30, 2025 | |||||||
| Risk-free interest rate | - | % | ||||||
| Dividend yield | - | - | ||||||
| Expected term (years) | - | |||||||
| Volatility | - | % | ||||||
Activity under the Plans for the period from December 31, 2025 to September 30, 2026 is set forth below:
| Number Outstanding | Weighted- Average Exercise Price Per Share | Weighted- Average Remaining Contractual Life (Years) | Aggregate Intrinsic Value | |||||||||||||
| Outstanding as of December 31, 2025 | $ | $ | - | |||||||||||||
| Granted | - | - | - | - | ||||||||||||
| Exercised | - | - | - | - | ||||||||||||
| Canceled/forfeited/expired | ( | ) | - | - | ||||||||||||
| Outstanding as of September 30, 2026 | $ | $ | - | |||||||||||||
| Options vested and exercisable at September 30, 2026 | $ | $ | - | |||||||||||||
| Options vested and expected to vest as of September 30, 2026 | $ | $ | - | |||||||||||||
The weighted average grant-date fair value of options granted during the nine month ended September 30, 2025 was $
Total equity-based compensation expense and the allocation of equity-based compensation for the periods presented below were as follows:
| Three Months Ended September 30, | Nine months ended September 30, | |||||||||||||||
| 2026 | 2025 | 2026 | 2025 | |||||||||||||
| General and administrative | $ | $ | $ | $ | ||||||||||||
| Research and development | ||||||||||||||||
| Total equity-based compensation | $ | $ | $ | $ | ||||||||||||
18
Note 8. Net Loss Per Share
The following table sets forth the computation of the basic and diluted net loss per common share:
| Three Months Ended September 30, | Nine Months Ended September 30, | |||||||||||||||
| 2026 | 2025 | 2026 | 2025 | |||||||||||||
| Numerator: | ||||||||||||||||
| Net loss | $ | ( | ) | $ | ( | ) | $ | ( | ) | $ | ( | ) | ||||
| Denominator: | ||||||||||||||||
| Weighted average common shares outstanding | ||||||||||||||||
| Net loss per common share, basic and diluted | $ | ( | ) | $ | ( | ) | $ | ( | ) | $ | ( | ) | ||||
Since the Company was in a loss position for the periods presented, basic net loss per share is the same as diluted net loss per share as the inclusion of all potential dilutive securities would have been anti-dilutive. For the periods presented, there were no potential dilutive securities other than stock options and warrants.
The following Common Stock equivalents were excluded from the calculation of diluted net loss per share applicable to common stockholders for the periods indicated because including them would have had an anti-dilutive effect:
| As of September 30, | ||||||||
| 2026 | 2025 | |||||||
| Anti-dilutive common stock equivalents: | ||||||||
| Stock options to purchase common stock | ||||||||
| Warrants to purchase common stock | ||||||||
| Total anti-dilutive common stock equivalents | ||||||||
Note 9. Leases, Commitments, and Contingencies
Leases
In accordance with ASC 842, Leases, the Company determines if an arrangement is or contains a lease at inception. A contract is or contains a lease if the contract conveys the right to control the use of an identified asset for a period of time in exchange for consideration.
At lease inception, the Company determines whether an arrangement is an operating or finance lease. For operating leases, the Company recognizes rent expense, inclusive of rent escalation, on a straight-line basis over the lease term.
The Company classifies leases at the lease commencement date as operating or finance leases and records a right-of-use asset and a lease liability on the balance sheets for all leases with an initial lease term of greater than 12 months. Leases with an initial term of 12 months or less are not recorded in the balance sheets pursuant to the practical expedient available under ASC 842, but payments are recognized as expenses on a straight-line basis over the lease term.
19
Finance and operating right-of-use assets and lease liabilities are recognized at the lease commencement date based on the present value of the lease payments over the lease term using the discount rate implicit in the lease. If the rate implicit is not readily determinable, the Company utilizes an estimate of its incremental borrowing rate based upon the available information at the lease commencement date. Operating lease assets are further adjusted for prepaid or accrued lease payments. Operating lease expense is recognized on a straight-line basis over the lease term.
In October 2025, the Company amended its office space lease to extend the term by one additional year. The lease agreement (as amended in October 2026) has a term that extends through April 30, 2027. Operating lease expenses were $
Future annual lease payments under non-cancellable operating leases as of September 30, 2026 were as follows:
| 2026 | $ | |||
| Total lease payments | $ |
Contingencies
In the normal course of business, the Company enters into contracts and agreements that contain a variety of representations and warranties and provide for general indemnifications. The Company’s exposure under these agreements is unknown, because it involves claims that may be made against the Company in the future, but have not yet been made. The Company accrues a liability for such matters when it is probable that future expenditures will be made and such expenditures can be reasonably estimated.
Indemnification
In accordance with the Company’s certificate of incorporation and bylaws, the Company indemnifies its officers and directors for certain events or occurrences, subject to certain limits, while they are serving in such capacity. In addition, the Company has entered into indemnification agreements with its officers and directors. There have been no claims to date, and the Company has a directors and officers liability insurance policy that may enable it to recover a portion of any amounts paid for future claims.
Note 10. Subsequent Events
The Company has evaluated events that occurred through November 16, 2026, the date that the financial statements were issued, and determined that there have been no events that have occurred that would require adjustments to its disclosures in the financial statements except for the transactions described below.
On October 9, 2026, the Board approved a grant of stock options to purchase up to an aggregate of
20
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations
You should read the following management’s discussion and analysis of our financial condition and results of operations in conjunction with our unaudited financial statements and notes thereto included in Part I, Item 1 of this Quarterly Report on Form 10-Q and with our audited financial statements and notes thereto for the year ended December 31, 2025, included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2025 filed on March 31, 2026 ((the “Annual Report”) with the U.S. Securities and Exchange Commission (the “SEC”). This discussion, particularly information with respect to our future results of operations or financial condition, business strategy, plans and objectives for future operations, includes forward-looking statements that involve risks and uncertainties as described under the heading “Special note regarding forward-looking statements” in this Quarterly Report on Form 10-Q. You should review the disclosure under Part I, Item 1A of the Annual Report for a discussion of important factors that could cause our actual results to differ materially from those anticipated in these forward-looking statements. References in this Quarterly Report on Form 10-Q to “we,” “us,” “our” and similar first-person expressions refer to Cadrenal Therapeutics, Inc. (“Cadrenal”).
Special Note Regarding Forward-Looking Statements
This Quarterly Report on Form 10-Q contains forward-looking statements that involve risks and uncertainties. Our actual results could differ materially from those discussed in the forward-looking statements. The statements contained in this report that are not purely historical are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”) and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). Forward-looking statements are often identified by the use of words such as, but not limited to, “anticipate,” “believe,” “can,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “project,” “seek,” “should,” “strategy,” “target,” “will,” “would” and similar expressions or variations intended to identify forward-looking statements. These statements are based on the beliefs and assumptions of our management based on information currently available to management. Such forward-looking statements are subject to risks, uncertainties and other important factors that could cause actual results and the timing of certain events to differ materially from future results expressed or implied by such forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, those identified under Part 1, Item 1A of the Annual Report. Furthermore, such forward-looking statements speak only as of the date of this report. Except as required by law, we undertake no obligation to update any forward-looking statements to reflect events or circumstances after the date of such statements.
Company Overview
We are a late-stage biopharmaceutical company advancing novel therapies for life-threatening immune and thrombotic conditions. Our development pipeline is anchored by four assets targeting acute medical needs:
| ● | CAD-1005: A first-in-class 12-lipoxygenase (12-LOX) inhibitor being developed for Heparin-Induced Thrombocytopenia (HIT) and Cardiac Surgery-Associated Acute Kidney Injury (CSA-AKI). |
| ● | Tecarfarin: A late-stage Vitamin K antagonist (VKA) designed to prevent systemic thromboembolism. |
| ● | Frunexian: An intravenous Factor XIa inhibitor. |
| ● | CAD-2000: Our next-generation oral 12-LOX platform. |
FDA Alignment on Phase 3 Registrational Trial for CAD-1005
On August 31, 2026, we announced positive feedback from a Type D meeting with the U.S. Food and Drug Administration (FDA) held on July 28, 2026.. During the meeting, we and the FDA aligned on key aspects of the protocol and Statistical Analysis Plan (SAP) for our Phase 3 registrational study of CAD-1005 in patients with HIT.
Key clinical consensus items included:
| ● | Primary Endpoint Protocol: Agreement on an optimized definition of worsening HIT for the primary endpoint, measured through Day 14 or hospital discharge. The endpoint will assess the proportion of Serotonin Release Assay-positive (SRA+) participants with adjudicated new or worsening composite thromboembolic events. |
21
| ● | Reduced Site Variability: The worsening component incorporates strict metrics assessing the extension of an existing thrombus into a new vascular segment or bed, avoiding potential site to site variability from manual size measurement. |
| ● | Trial Architecture: The FDA agreed to use placebo control in the Phase 3 trial, with existing standard anticoagulation therapeutics for both the CAD-1005 and placebo control arms. |
CAD-1005 continues to hold valuable FDA Orphan Drug and Fast Track designations, along with orphan drug status from the European Medicines Agency (EMA).
Engagement of Strategic Financial Advisor
On October 7, 2026, building on our pipeline’s regulatory maturity and ongoing inbound interest, our Board of Directors initiated a formal strategic review to maximize our value and the value of our asset portfolio. In connection with this initiative, we retained Tungsten Advisors as our exclusive strategic financial advisor to lead the review.
The strategic review will evaluate multiple structural alternatives to maximize portfolio value, including:
| ● | Asset Monetization: Out-licensing, regional co-development rights, or the outright sale of individual pipeline assets like CAD-1005 or tecarfarin. |
| ● | Strategic Alliances: Deep operational and commercialization partnerships with global pharmaceutical entities. |
| ● | Corporate Transactions: Corporate mergers, portfolio combinations, or other comprehensive business combinations. |
There is no assurance that this strategic review process will result in any definitive transaction. We do not intend to disclose further developments regarding this process unless or until our Board of Directors has approved a specific transaction or formally concluded the review, or the Company otherwise determines that disclosure id appropriate or required.
Strategic Status of Alternative Assets
While our strategic evaluation process centers on the clinical positioning of CAD-1005, the Board of Directors and Tungsten Advisors are concurrently evaluating strategic paths to maximize the inherent value of our alternative pipeline assets, tecarfarin and frunexian:
| ● | Tecarfarin: Our late-stage Vitamin K antagonist (VKA) is being designed to avoid the metabolic pathways that cause unpredictable dosing and side effects seen with traditional anticoagulants. Given its advanced development stage and historical data, the strategic review is focusing on out-licensing opportunities in specific geographic territories or for specialized patient populations—such as patients with end-stage renal disease (ESRD) and atrial fibrillation or those requiring mechanical heart valve, including implemented left ventricular assist devices (LVADs)—where direct oral anticoagulants (DOACs) are currently contraindicated. |
| ● | Tecarfarin Regulatory Developments (RPDD Amendment): On October 22, 2026, we systematically responded to an FDA Office of Orphan Products Development deficiency letter regarding our Rare Pediatric Disease Designation (RPDD) request (# RPD-2026-1250). To align with the Agency’s guidance, we formally restricted our proposed pediatric indication to a severe, anatomically verifiable sub-population: the prevention of acute myocardial infarction and luminal occlusion in pediatric patients with Chronic Kawasaki Disease-Induced Giant Coronary Artery Aneurysms. Longitudinal epidemiological models submitted to the FDA project that this limits the newly eligible annual target prevention pool to approximately 28 to 55 patients across the United States, well below the statutory ceilings required for rare disease classification. |
| ● | Frunexian: Our intravenous Factor XIa inhibitor is being developed for acute and critical care settings, including major cardiac surgery. Strategic alternatives under consideration include co-development alliances and joint ventures with global pharmaceutical partners to fund and accelerate its clinical development, thereby mitigating our independent research and development financial exposure. |
Recent Financing Developments
PIPE Transaction
On June 30, 2026, we entered into a securities purchase agreement with an investor, pursuant to which we issued and sold, in a private placement priced at-the-market under the rules of the Nasdaq Stock Market (the “PIPE Transaction”), (i) pre-funded warrants (the “Pre-Funded Warrants”) to purchase up to an aggregate of 960,000 shares (the “Pre-Funded Warrant Shares”) of our common stock, par value $0.001 per share (the “Common Stock”), (ii) Series C-1 Common Stock warrants (the “Series C-1 Warrants”) to purchase up to an aggregate of 960,000 shares (the “Series C-1 Warrant Shares”) of Common Stock, and (iii) Series C-2 Common Stock warrants (the “Series C-2 Warrants” and, together with the Series C-1 Warrants, the “Common Warrants”) to purchase up to an aggregate of 960,000 shares (the “Series C-2 Warrant Shares” and, together with the Pre-Funded Warrant Shares and the Series C-1 Warrant Shares, the “PIPE Warrant Shares”) of Common Stock, at a combined purchase price of $3.1249 per Pre-Funded Warrant and accompanying Common Warrants. We received aggregate gross proceeds of approximately $3.0 million, before deducting placement agent fees and other offering expenses.
22
The Pre-Funded Warrants have an exercise price of $0.0001 per share, are exercisable immediately, and do not expire until exercised in full. The Series C-1 Warrants and Series C-2 Warrants each have an exercise price of $3.00 per share. The Series C-1 Warrants become exercisable beginning on the effective date of stockholder approval of the issuance of the Series C-1 Warrant Shares (the “Stockholder Approval”) and will expire five years after the later of the effective date of Stockholder Approval or the effective date of a resale registration statement registering for resale all of the Series C-1 Warrant Shares. The Series C-2 Warrants are exercisable immediately upon issuance and expire 24 months after the earliest of the date that (a) the initial registration statement registering for resale all Pre-Funded Warrant Shares and Series C-2 Warrant Shares has been declared effective by the SEC, (b) all of the PIPE Warrant Shares have been sold pursuant to Rule 144 or may be sold pursuant to Rule 144 without the requirement for us to be in compliance with the current public information required under Rule 144 and without volume or manner-of-sale restrictions, (c) following the one year anniversary of the closing of the PIPE Transaction, provided that a holder of PIPE Warrant Shares is not an affiliate of ours, or (d) all of the PIPE Warrant Shares may be sold pursuant to an exemption from registration under Section 4(a)(1) of the Securities Act, without volume or manner-of-sale restrictions (the “Effective Date”). A resale registration statement registering the resale of all of the PIPE Warrant Shares was declared effective by the SEC on July 20, 2026. Stockholder Approval was obtained at our 2026 annual meeting of stockholders (the “2026 Annual Meeting:) held on September 24, 2026. During the three months ended September 30, 2026, the holder exercised all 960,000 Pre-Funded Warrants.
H.C. Wainwright & Co., LLC (“H.C.W.”) served as our exclusive placement agent in connection with the PIPE Transaction. As compensation for H.C.W. serving as our placement agent in connection with the PIPE Transaction, we paid H.C.W. a cash fee equal to 7.0% of the aggregate gross proceeds received, a management fee of 1.0% of the aggregate gross proceeds, $25,000 for non-accountable expenses and up to $50,000 for legal and other out-of-pocket expenses, and issued to designees of H.C.W. unregistered warrants (the “Placement Agent Warrants”) to purchase up to an aggregate of 62,400 shares of Common Stock, equal to 6.5% of the Pre-Funded Warrant Shares sold in the PIPE Transaction. The Placement Agent Warrants have substantially the same terms as the Series C-1 Warrants, except that they are immediately exercisable for a term of five years from the Effective Date and have an exercise price of $3.9063 per share.
April 2026 Warrant Inducement
On March 31, 2026, we entered into a warrant inducement letter agreement (the “Inducement Agreement”) with a holder of warrants to purchase shares of our Common Stock, which warrants were issued in a private placement offering that closed on November 4, 2024 (the “Existing Warrants”). Pursuant to the Inducement Agreement, on April 1, 2026, the holder of the Existing Warrants exercised for cash the Existing Warrants to purchase up to an aggregate of 571,430 shares of Common Stock, at the adjusted exercise price of $4.50 per share (reduced from the initial exercise price of $16.50 per share) and, in consideration for the investor’s exercise of the Existing Warrants, we issued to such investor new unregistered Series B-1 Common Stock purchase warrants (the “Series B-1 Warrants”) to purchase an aggregate of 571,430 shares of Common Stock and new unregistered Series B-2 Common Stock purchase warrants (the “Series B-2 Warrants” and, together with the Series B-1 Warrants, the “New Warrants”) to purchase an aggregate of 571,430 shares of Common Stock. The New Warrants are immediately exercisable at an exercise price of $4.50 per share. We received aggregate gross proceeds of approximately $2.6 million from the exercise of the Existing Warrants, before deducting placement agent fees and other expenses payable by us. The Series B-1 Warrants and the Series B-2 Warrants are immediately exercisable for a term of five (5) years and eighteen (18) months, respectively, from the date that a resale registration statement registering the resale of the shares of Common Stock issuable upon exercise of the New Warrants (the “Resale Registration Statement”) is declared effective by the SEC. The Resale Registration Statement was declared effective on April 29, 2026.
H.C.W. served as our exclusive placement agent in connection with the transactions consummated pursuant to the Inducement Agreement. As compensation for H.C.W. serving as our placement agent in connection with the offering, we paid H.C.W. a cash fee equal to 7.0% of the aggregate gross proceeds received upon exercise of the Existing Warrants and we issued to designees of H.C.W. warrants to purchase up to 37,143 shares of Common Stock, which warrants have substantially the same terms as the Series B-1 Warrants, except that they have an exercise price of $5.625 per share, which is equal to 125% of the exercise price of the New Warrants.
23
ATM Facility
During the nine months ended September 30, 2026, we sold 189,035 shares of our Common Stock through our at-the-market (ATM) facility with H.C.W. These sales were made at a weighted average price of $7.71 per share, resulting in total gross proceeds of $1,458,088 and net proceeds of $1,382,669. During the three months ended September 30, 2026, there were no sales of shares of our Common Stock through our ATM facility with H.C.W.
Other Recent Developments
On September 24, 2026, at our 2026 Annual Meeting, our stockholders approved an amendment to the 2022 Plan to increase the number of shares of the Company’s Common Stock that will be available for awards under the 2022 Plan by 323,542 shares to 1,000,000 shares. As of September 30, 2026, 658,129 shares remained available for future issuance. Subsequently, on October 9, 2026, the Board approved a grant of stock options to purchase up to an aggregate of 575,000 shares of Common Stock to our officers and directors, which options have an exercise price of $0.91 per share, vested in full immediately upon grant and are exercisable for a term of ten years.
Results of Operations
Results of Operations for the Three Months Ended September 30, 2026 and 2025
The following table summarizes our results of operations for the three months ended September 30, 2026 and 2025.
| Three Months Ended September 30, | ||||||||||||||||
| 2026 | 2025 | $ Change | % Change | |||||||||||||
| Operating expenses: | ||||||||||||||||
| General and administrative expenses | $ | 1,040,335 | $ | 2,044,937 | $ | (1,004,602 | ) | (49 | %) | |||||||
| Research and development expenses | 224,576 | 688,465 | (463,889 | ) | (67 | %) | ||||||||||
| Depreciation expense | 400 | 401 | (1 | ) | (0 | %) | ||||||||||
| Total operating expenses | 1,265,311 | 2,733,803 | (1,468,492 | ) | (54 | %) | ||||||||||
| Loss from operations | (1,265,311 | ) | (2,733,803 | ) | 1,468,492 | (54 | %) | |||||||||
| Other income | ||||||||||||||||
| Interest and dividend income | 18,440 | 48,098 | (29,658 | ) | (62 | %) | ||||||||||
| Total other income | 18,440 | 48,098 | (29,658 | ) | (62 | %) | ||||||||||
| Net loss and comprehensive loss | $ | (1,246,871 | ) | $ | (2,685,705 | ) | $ | 1,438,834 | (54 | %) | ||||||
General and administrative expenses
General and administrative expenses were $1.0 million for the three months ended September 30, 2026, compared to $2.0 million for the three months ended September 30, 2025, a decrease of approximately $1.0 million, or 49%. The decrease was primarily attributable to a $0.7 million decrease in expenses related to being a public company and a $0.3 million decrease in stock based compensation expense.
Research and development expenses
Research and development expenses were $0.2 million for the three months ended September 30, 2026, compared to $0.7 million for the three months ended September 30, 2025, a decrease of approximately $0.5 million, or 67%. The decrease was primarily attributable to $0.2 million in expenses associated with our acquisition of frunexian pursuant to the asset purchase agreement that we entered into with eXIthera Pharmaceuticals (“eXIthera APA”) completed in September 2025,which were expensed as in-process research and development (“R&D”) in 2025, $0.2 million decrease in expenses associated with chemistry, manufacturing, and controls (“CMC”) and a $0.1 million decrease in stock-based compensation expense. We expect research and development expenses to increase if we commence clinical trials.
24
Interest and dividend income
Interest and dividend income was $18,440 for the three months ended September 30, 2026, compared to $48,098 for the three months ended September 30, 2025, a decrease of $29,658, or 62%, reflecting interest and dividend income earned on our investments in money market funds.
Results of Operations for the Nine Months Ended September 30, 2026 and 2025
The following table summarizes our results of operations for the nine months ended September 30, 2026 and 2025.
| Nine Months Ended September 30, | ||||||||||||||||
| 2026 | 2025 | $ Change | % Change | |||||||||||||
| Operating expenses: | ||||||||||||||||
| General and administrative expenses | $ | 5,417,396 | $ | 6,955,907 | $ | (1,538,511 | ) | (22 | %) | |||||||
| Research and development expenses | 1,701,235 | 3,433,845 | (1,732,610 | ) | (50 | %) | ||||||||||
| Depreciation expense | 1,459 | 6,319 | (4,860 | ) | (77 | %) | ||||||||||
| Total operating expenses | 7,120,090 | 10,396,071 | (3,275,981 | ) | (32 | %) | ||||||||||
| Loss from operations | (7,120,090 | ) | (10,396,071 | ) | 3,275,981 | (32 | %) | |||||||||
| Other income | ||||||||||||||||
| Interest and dividend income | 54,114 | 197,699 | (143,585 | ) | (73 | %) | ||||||||||
| Total other income | 54,114 | 197,699 | (143,585 | ) | (73 | %) | ||||||||||
| Net loss and comprehensive loss | $ | (7,065,976 | ) | $ | (10,198,372 | ) | $ | 3,132,396 | (31 | %) | ||||||
General and administrative expenses
General and administrative expenses for the nine months ended September 30, 2026 and 2025 were $5.4 million and $7.0 million, respectively, representing a decrease of approximately $1.5 million, or 22%. The decrease is primarily attributed to a $1.2 million decrease in expenses related to being a public company, a $0.3 million decrease in stock-based compensation. and a $0.3 million decrease in consulting expenses. These decreases were offset by a $0.3 million increase in personnel-related expenses as a result of our former Chief Financial Officer’s severance agreement entered into in June 2026 and implemented annual pay raises for management in January 2026.
Research and development expenses
Research and development expenses for the nine months ended September 30, 2026 and 2025 were $1.7 million and $3.4 million, respectively, representing a decrease of $1.7 million, or 50%. The decrease is primarily attributed to a $1.3 million decrease in expenses associated with CMC, a $0.2 million decrease in expenses associated with our acquisition of frunexian pursuant to the eXIthera APA completed in September 2025 which were expense as in-process R&D, a $0.3 million decrease in stock-based compensation, a $0.3 million decrease in personnel-related expenses, and a $0.1 million decrease in clinical trial preparation costs. These decreases were offset by a $0.5 million increase in consulting expenses.
Interest and dividend income
Interest and dividend income for the nine months ended September 30, 2026 and 2025 were $0.1 million and $0.2 million, respectively. This represents the interest and dividend income earned from our investments in money market funds.
Liquidity and Capital Resources
Since inception, we have incurred recurring losses and utilized cash in operations. To date, we have funded our operations from the proceeds of the sale of convertible and promissory notes, our initial public offering completed in January 2023, our private placement offering completed in July 2023, our warrant inducements completed in November 2024 and April 2026, our private placement offering in June 2026, our registered direct offering and concurrent private placement completed in December 2025, and the sale of Common Stock through our ATM facility with H.C.W.
25
Our historical general and administrative (G&A) expense trajectory related to executive personnel remains unchanged by the formal appointment of Mr. Pham as Chief Business Officer, given the zero-additional-cost nature of the arrangement. Retaining Tungsten Advisors to lead our strategic review process is expected to increase professional, legal, and advisory fees in the fourth quarter of 2026 and potentially into fiscal year 2027. These costs include fixed advisory fees as well as success-based transaction metrics contingent upon completing a strategic combination or asset sale.
As of September 30, 2026, we had cash and cash equivalents of $3.1 million. For the nine months ended September 30, 2026 we reported a net loss of $7.1 million, which included $1.0 million of non-cash expenses, and cash used in operating activities of $7.2 million. We expect to continue to incur operating losses and negative cash flows for the foreseeable future if we are able to advance our clinical and regulatory activities. Based on our current operating plan, we believe that our existing cash resources will not be sufficient to fund our operating and capital requirements for the next 12 months. With our cash position of $2.7 million as of early November 2026, we believe our current capital resources are sufficient to meet immediate operating needs through the first quarter of 2027. However, our long-term liquidity profile and ability to fund any Phase 3 trial remain heavily dependent on securing non-dilutive capital, strategic licensing fees, or equity financing arising from the ongoing strategic evaluation process. To date, we have not been successful in raising sufficient funds to allow us to complete any clinical trials, and we will not commence a trial that we do not believe we have sufficient funding to complete. No assurances can be provided and our cash runway could differ materially from our expectations based on various factors, many of which are out of our control. To meet our capital needs, management is focusing on securing additional funds, which may include strategic partnerships, out-licensing agreements, or alternative non-dilutive funding or sales under our ATM facility with H.C.W., equity offerings, debt financings, or a combination thereof. However, there can be no assurance that we will be able to complete partnering transactions or financings on terms acceptable to us or at all or that we will be awarded any grant funding. These factors raise substantial doubt about our ability to continue as a going concern for at least one year following the issuance of the accompanying financial statements. If we are unable to monetize our assets or obtain additional funding, we may be required to delay, scale back or discontinue development programs, liquidate intellectual property or other assets, or cease operations entirely. The accompanying financial statements do not include any adjustments that might result from this uncertainty.
Because of the uncertainty our ability to raise sufficient capital, on October 7, 2026, we announced that our Board of Directors initiated a formal strategic process to evaluate opportunities to maximize the value of the Company and our assets. Potential opportunities may include licensing or sale of individual assets, development and commercialization partnerships, portfolio transactions, business combinations, reverse merger or other strategic transactions.
Cash Flows
The following table summarizes our cash flows for the period presented:
| Nine Months Ended September 30, | ||||||||
| 2026 | 2025 | |||||||
| Cash used in operating activities | $ | (7,150,976 | ) | $ | (10,031,707 | ) | ||
| Cash used in investing activities | - | (5,104 | ) | |||||
| Cash provided by financing activities | 6,199,273 | 3,878,951 | ||||||
| Net change in cash | (951,703 | ) | (6,157,860 | ) | ||||
| Cash and cash equivalents, beginning of period | 4,007,789 | 10,017,942 | ||||||
| Cash and cash equivalents, end of period | $ | 3,056,086 | $ | 3,860,082 | ||||
Operating activities
During the nine months ended September 30, 2026, cash used in operating activities was $7.2 million. Net loss adjusted for the non-cash items as detailed on the statement of cash flows, used $6.0 million in cash, and the changes in operating assets and liabilities, as detailed on the statement of cash flows, used $1.1 million in cash primarily from a $0.9 million decrease in accrued liabilities, a $0.2 million decrease in accounts payable, and a $0.1 million increase in prepaid expenses.
During the nine months ended September 30, 2025, cash used in operating activities was $10.0 million. Net loss adjusted for the non-cash items as detailed on the statement of cash flows, used $8.6 million in cash, and the changes in operating assets and liabilities, as detailed on the statement of cash flows, used $1.5 million in cash primarily from a $0.9 million decrease in accounts payable, a $0.4 million decrease in accrued liabilities, and a $0.1 million increase in prepaid expenses.
26
Financing activities
During the nine months ended September 30, 2026, net cash provided by financing activities totaled $6.2 million primarily consisting of $2.6 million net proceeds from warrant issuances, $2.2 million net proceeds received from the April 2026 warrant inducement and $1.4 million received upon the sales of Common Stock in our ATM facility.
During the nine months ended September 30, 2025, net cash provided by financing activities totaled $3.9 million from the sale of Common Stock in our ATM facility and proceeds from the exercise of stock options.
Critical Accounting Estimates
This discussion and analysis of our financial condition and results of operations is based on our financial statements, which have been prepared in accordance with generally accepted accounting principles in the United States, or GAAP. The preparation of these financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported expenses incurred during the reporting periods. Significant estimates and assumptions made in the accompanying financial statements include but are not limited to the fair value of financial instruments, the fair value of stock-based awards, deferred tax assets and valuation allowance, income tax uncertainties, and certain accruals. Our estimates are based on our historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimated under different assumptions or conditions.
Stock-Based Compensation
We measure our stock-based awards granted to employees, consultants and directors based on the estimated grant-date fair values of the awards and recognize the compensation over the requisite service period. We use the Black-Scholes option-pricing model to estimate the fair value of our stock option awards. Stock-based compensation is recognized using the straight-line method. As the stock compensation expense is based on awards ultimately expected to vest, it is reduced by forfeitures. We account for forfeitures as they occur.
OFF-BALANCE SHEET ARRANGEMENTS
We did not have during the periods presented, and we do not currently have, any off-balance sheet arrangements, as defined under SEC rules.
Item 3. Quantitative and Qualitative Disclosures About Market Risk.
Not applicable because we are a smaller reporting company.
Item 4. Controls and Procedures.
Evaluation of Disclosure Controls and Procedures
Our management, with the participation of our Chief Executive Officer and Interim Chief Financial Officer, evaluated the effectiveness of our disclosure controls and procedures as of September 30, 2026. The term “disclosure controls and procedures,” as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act, means controls and other procedures of a company that are designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the company’s management, including its principal executive and principal financial officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure. We have adopted and maintain disclosure controls and procedures (as defined Rules 13a-15(e) and 15d-15(e) under the Exchange Act) that are designed to provide reasonable assurance that information required to be disclosed in the reports filed under the Exchange Act, such as this Quarterly Report on Form 10-Q, is collected, recorded, processed, summarized, and reported within the time periods specified in the rules of the SEC. Our disclosure controls and procedures are also designed to ensure that such information is accumulated and communicated to management to allow timely decisions regarding required disclosure. Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Based on the evaluation of our disclosure controls and procedures as of September 30, 2026, our Chief Executive Officer and Interim Chief Financial Officer concluded that, as of such a date, our disclosure controls and procedures were effective at the reasonable assurance level.
Changes in Internal Control over Financial Reporting
During the quarter ended September 30, 2026, there were no changes in our internal control over financial reporting (as defined in Rules 13a 15(f) and 15d 15(f) of the Exchange Act) that occurred that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.
27
PART II: OTHER INFORMATION
Item 1. Legal Proceedings
We are not currently subject to any material legal proceedings.
Item 1A. Risk Factors
Investing in our securities involves a high degree of risk. Please refer to Part I, Item 1A, “Risk Factors,” contained in our Annual Report for a description of certain significant risks and uncertainties to which our business, financial condition and results of operations are subject. Except as set forth below, there have been no material changes from these risk factors as of the date of filing of this Quarterly Report on Form 10-Q.
Our financial statements have been prepared assuming that we will continue as a going concern.
We had an accumulated deficit of approximately $46.0 million as of September 30, 2026 and a net loss of approximately $7.1 million for the nine months ended September 30, 2026. We believe that our existing cash and cash equivalents will not be sufficient to meet our anticipated cash requirements for the next twelve months. We will require additional financing in order to execute our business strategy, including additional funds to advance our product candidates to clinical trial readiness or to commence any clinical trials. Our unaudited financial statements for the nine months ended September 30, 2026 were prepared under the assumption that we will continue as a going concern; however, we have incurred significant losses from operations to date and we expect our expenses to increase if we are able to raise sufficient funding to advance our product candidates to clinical trials readiness. These factors raise substantial doubt about our ability to continue as a going concern for one year after the financial statements are issued. Our unaudited financial statements for the quarter ended September 30, 2026 contain an explanatory paragraph with respect to this uncertainty. In addition, in connection with the filing of our Annual Report, our independent registered public accounting firm issued a report that included an explanatory paragraph with respect to this uncertainty. Our liquidity may be negatively impacted as a result of research and development cost increases in addition to general economic and industry factors. In order to meet our expected capital needs, management is focusing on securing additional funds, which may include strategic partnerships, out-licensing agreements, non-dilutive grant funding, sales under our ATM facility with H.C.W., equity offerings, debt financings, or a combination thereof. However, there can be no assurance that we will be able to complete partnering transactions or financings on terms acceptable to us or at all or that we will be awarded any grant funding. The various ways that we could raise capital carry potential risks. Any additional financing will likely involve the issuance of our equity securities, which will have a dilutive effect on our stockholders. Any debt financing, if available, may involve restrictive covenants that may impact our ability to conduct our business. If we raise funds through partnering, such as collaborations and licensing arrangements, we might be required to relinquish significant rights to our technologies or grant licenses on terms that are not favorable to us. If we do not succeed in raising additional funds on acceptable terms or at all, we may be unable to advance our product candidates to clinical trial readiness or to complete any clinical trials. As such, we cannot conclude that such plans will be effectively implemented within one year after the date that the financial statements included in this Quarterly Report on Form 10Q are filed with the SEC and there is uncertainty regarding our ability to maintain liquidity sufficient to operate our business effectively, which raises substantial doubt about our ability to continue as a going concern.
28
We cannot be assured that we will be able to maintain our listing on the Nasdaq Capital Market.
Our securities are listed on The Nasdaq Capital Market, a national securities exchange. We cannot be assured that we will continue to comply with the rules, regulations or requirements governing the listing of our Common Stock on the Nasdaq Stock Market LLC (“Nasdaq”) or that our securities will continue to be listed on Nasdaq in the future. If Nasdaq should determine at any time that we fail to meet Nasdaq requirements, we may be subject to a delisting action by Nasdaq.
As reported in our Quarterly Report on Form 10-Q for the quarter ended March 31, 2026 our stockholders’ equity of $1.8 million as of March 31, 2026 was below the minimum stockholders’ equity requirement of at least $2,500,000 for continued listing on The Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(b)(1) (the “Stockholders’ Equity Requirement”). We believe that we regained compliance with the Stockholders’ Equity Requirement as a result of our receipt of net proceeds of $2.2 million from the exercise of the Existing Warrants in connection with the warrant inducement we consummated on April 1, 2026. As of September 30, 2026, our stockholders’ equity was $2.9 million, only approximately $0.4 million above the $2.5 million minimum stockholders’ equity requirement, and there can be no assurance that we will be able to maintain compliance with this requirement, particularly if we continue to incur operating losses.
On July 22, 2026, the SEC approved Nasdaq’s recently proposed rule changes to (i) adopt NASDAQ Listing Rule 5550(a)(6) to require issuers listed on the Nasdaq Capital Market to maintain a minimum Market Value of Listed Securities (as defined in Nasdaq Listing Rule 5005(a)(23)) (“MVLS”) of at least $5 million for a period of thirty (30) consecutive business days, and (ii) amend Rule 5810 to suspend trading and immediately delist from Nasdaq securities of issuers that do not satisfy the proposed new requirements, and Rule 5815 to set forth the procedures for requesting a hearing before a Hearings Panel and the scope of the Panel’s discretion. MVLS is generally calculated by multiplying the consolidated closing bid price by the number of shares of listed securities outstanding and, where a company has more than one class or series of equity security listed on Nasdaq, the values are aggregated. Under the new rule, if a company’s MVLS remains below $5 million for 30 consecutive business days, Nasdaq will issue a Staff Delisting Determination and immediately suspend trading of the company’s securities.
Unlike many other Nasdaq continued listing standards, the new MVLS requirement does not provide a compliance or cure period before a Staff Delisting Determination is issued. Additionally, a request for a hearing before the Hearings Panel does not automatically stay the suspension of trading. While the Hearings Panel may reverse a Staff Delisting Determination if it concludes that Nasdaq made an error, or in limited circumstances grant an exception of up to 180 calendar days for a company to demonstrate compliance with Nasdaq’s initial listing standards — which are generally more stringent than the continued listing standards — there can be no assurance that any such relief would be granted. A company may further appeal an adverse Hearings Panel decision to the Nasdaq Listing and Hearing Review Council; however, the company’s securities would generally trade in the over-the-counter market during the pendency of any such appeal.
However, on July 29, 2026, Nasdaq’s new continued listing requirement requiring companies to maintain at least $5 million in MVLS was automatically stayed. For now, Nasdaq’s new $5 million MVLS continued listing requirement is not effective. The SEC must decide whether to review the approval and, if it does, whether to affirm, modify, reverse, set aside, or remand the matter for further proceedings. We cannot predict the timing or outcome of that review, whether or when the requirement will become operative, or the implementation and measurement procedures that may apply if the stay is lifted. The SEC may also decline review. During that process, the stay remains in place, and there is no prescribed timeline for the SEC to reach a decision. Because filing a petition for SEC review is generally a prerequisite to seeking judicial review, the matter could ultimately proceed to a federal court of appeals. If that occurs, the listing requirement could remain stayed during the pendency of the litigation, potentially delaying implementation for a significant period of time.
29
As of September 30, 2026, our MVLS is below $5 million. If the rule is adopted as proposed and our MVLS stays below $5 million for 30 consecutive business days after the rule takes effect, our Common Stock would be subject to immediate suspension and delisting. There can be no assurance that our MVLS will be at or above the $5 million threshold for periods long enough to comply with the new standard. To avoid delisting, if the new standard becomes effective, we would need to raise our MVLS to at least $5 million and keep it there. We may not be able to do so on a timely basis or at all.
If Nasdaq delists our securities from trading on its exchange at some future date, we would take actions to restore our compliance with The Nasdaq Capital Market’s listing requirements, but we can provide no assurance that any such action taken by us would allow our Common Stock to become listed again, stabilize the market price or improve the liquidity of our Common Stock, prevent our Common Stock from dropping below The Nasdaq Capital Market, minimum bid price requirement or prevent future non-compliance with The Nasdaq Capital Market’s listing requirements. In the event of a delisting, we could face significant material adverse consequences, including:
| ● | a limited availability of market quotations for our securities; |
| ● | reduced liquidity with respect to our securities; |
| ● | a determination that our Common Stock is a “penny stock” which will require brokers trading in our Common Stock to adhere to more stringent rules, possibly resulting in a reduced level of trading activity in the secondary trading market for our Common Stock; |
| ● | a limited amount of news and analyst coverage for our company; and |
| ● | a decreased ability to issue additional securities or obtain additional financing in the future. |
Our shift to a partnership and out-licensing strategy may not be successful, and if we are unable to secure partnerships, out-licensing arrangements, additional funding, or other strategic transactions, we may be unable to advance our pipeline candidates or continue operations.
We do not have the financial resources to independently fund Phase 3 clinical development of our pipeline candidates. Because of our liquidity constraints, management has formally pivoted our operating strategy. Instead of independently funding late-stage clinical development of our lead assets, we are pursuing out-licensing, portfolio monetization and strategic alliances, but there can be no assurance that we will be able to enter into any such transaction.
Strategic transactions and partnerships are inherently uncertain. They depend on negotiations with third parties that are beyond our control. Potential partners or acquirers may have limited interest in our programs or may require terms we consider unfavorable. Our weakened financial position may also reduce our negotiating leverage. There can be no assurance that we will be able to identify suitable counterparties, negotiate acceptable terms, obtain non-dilutive financing or complete any transaction on a timely basis or at all. Any agreement we do reach may provide less upfront or near-term cash than we need. It may also require us to give up significant rights to our product candidates, including future economics, development control or commercialization rights, on terms less favorable than we might obtain if we had greater financial resources.
We are also evaluating and exploring a variety of other strategic alternatives focused on maximizing stockholder value, including, but not limited to, an acquisition, merger, reverse merger, other business combination, sales of assets or other strategic transactions. Our ability to successfully execute on a strategic alternative is dependent on a number of factors and we may not be able to execute upon a transaction or other strategic alternative upon favorable terms within an advantageous timeframe and recognize significant value for our assets, if at all. Additionally, the negotiation and consummation of a transaction or other strategic alternative may be costly and time-consuming. Any executed strategic alternative may not maximize or even enhance stockholder value, could result in total costs and expenses that are greater than expected, could make it more difficult to attract and retain qualified personnel and may disrupt our operations, each of which could have a material adverse effect on our business.
The market price of our Common Stock may reflect a market assumption that a strategic alternative will occur, and a failure to complete a strategic alternative could result in negative investor perceptions and could cause a decline in the market price of our Common Stock, which could adversely affect our ability to access the equity and financial markets, as well as our ability to explore and enter into different strategic alternatives. There can be no certainty that any strategic alternative will be completed, be on attractive terms, enhance stockholder value or deliver the anticipated benefits, and successful integration or execution of the strategic alternatives will be subject to additional risks.
30
Even if we enter into a partnership, license or co-development arrangement, much of the economic value we expect will depend on our collaborators. Milestone payments and royalties typically depend on development, regulatory and commercial events that may never occur. Our collaborators may have significant discretion over the resources they commit to our programs. They may not devote enough resources, may prioritize other programs, including competing programs, or may fail to perform as expected. They may also terminate the arrangement or disagree with us over its terms. If we are unable to monetize our assets, secure partnerships or out-licensing arrangements or obtain additional funding, we may be required to cease operations entirely. In that case, our stockholders could lose all or part of their investment.
We have applied for a Rare Pediatric Disease Designation (RPDD) for tecarfarin, but we may not obtain this designation, and failure to do so could significantly diminish the asset’s strategic and out-licensing value.
We have submitted a request to the U.S. Food and Drug Administration (FDA) for a Rare Pediatric Disease Designation (RPDD) for tecarfarin for the treatment of a restricted pediatric population. On September 3, 2026, the FDA Office of Orphan Products Development issued a deficiency letter regarding our application, questioning whether the target condition qualified as a distinct rare disease. On October 22, 2026, we submitted a formal amendment refining our proposed indication strictly to the prevention of acute myocardial infarction and luminal occlusion in pediatric patients with Chronic Kawasaki Disease-Induced Giant Coronary Artery Aneurysms (defined by a localized Z-score ≥10 or absolute internal diameter ≥8 mm).
While we believe our refined population estimates and scientific rationale satisfy the statutory criteria under Section 529(a)(3) of the FD&C Act, there can be no assurance that the FDA will agree with our definition of the distinct disease entity or accept our revised population estimates. If the FDA does not grant this designation, we will not be eligible to receive a Rare Pediatric Disease Priority Review Voucher (PRV) upon potential regulatory approval of tecarfarin. Because our corporate strategy has shifted away from independent development toward pursuing out-licensing agreements, regional co-development rights, and strategic partnerships for our alternative assets, the failure to obtain RPDD status and the associated eligibility for a PRV could materially and adversely affect our negotiating leverage, reduce the upfront or milestone fees we might otherwise command from potential global pharmaceutical partners, or prevent us from successfully monetizing the tecarfarin asset entirely.
Our Board of Directors’ review of strategic alternatives may not result in a successful transaction, and the process could disrupt our business and adversely affect our stock price.
Because of uncertainty about our ability to raise sufficient capital, we announced on October 7, 2026 that our Board of Directors had begun a formal strategic process to evaluate opportunities to maximize the value of the Company and its assets. Potential opportunities may include licensing or selling individual assets, development and commercialization partnerships, portfolio transactions, business combinations, a reverse merger or other strategic transactions. We have not set a timetable for completing the process, and we may not disclose further developments unless and until the Board approves a specific transaction or decides to end the process. The Board may also decide that no transaction is in the best interests of our stockholders.
There can be no assurance that the strategic review will lead to any transaction or, if a transaction is completed, that it will create value for our stockholders. The terms of any transaction may be less favorable than expected. A transaction, such as a reverse merger or business combination, could substantially dilute our current stockholders or place their investment in a business that is significantly different from our current one. Completing a transaction may also depend on conditions we do not control, such as stockholder approval, regulatory approvals and the counterparty’s own financing. If the review does not produce a transaction, or if a proposed transaction is not completed, we may have to pursue other alternatives on less favorable terms. These could include a dissolution and liquidation of the Company, in which case the amount, if any, distributed to stockholders could be significantly lower than the current market price of our common stock.
The strategic review requires substantial management time and attention, as well as significant financial resources. These costs include fees for financial, legal and other advisors, and we will incur them whether or not a transaction is completed. Speculation about the outcome or timing of the process, or a negative market view of it, could cause our stock price to fall or become more volatile. It could also make it harder to raise capital on our own.
31
The review process could also disrupt our operations. Uncertainty about its outcome may make it harder to attract and retain key scientific and administrative personnel, maintain relationships with clinical investigators, vendors and other business partners, and keep early-stage research programs moving at our historical pace. Any of these effects could harm our business, financial condition and results of operations, and could make us less attractive to potential partners or acquirers.
The terms of our recent PIPE Transaction may limit our ability to raise additional capital, and failure to satisfy our registration obligations could require us to make payments that would reduce the cash available to fund our operations.
In connection with the PIPE Transaction, we agreed to certain restrictions on issuing Common Stock or common stock equivalents and filing new registration statements for a period following the applicable effective date, subject to limited exceptions. We also agreed not to enter into variable-rate transactions for a period of one year following the applicable effective date, subject to a limited exception permitting sales under our at-the-market facility beginning 60 days after such effective date. Because we expect to require substantial additional capital, these restrictions could limit our ability to raise capital on favorable terms, or at all, during the restricted periods.
The issuance and resale of shares of Common Stock underlying outstanding warrants may result in substantial dilution and could adversely affect the market price of our Common Stock.
We have outstanding warrants to purchase a significant number of shares of our Common Stock, including the Series C-1 Warrants, Series C-2 Warrants and Placement Agent Warrants that we issued in connection with the PIPE Transaction. We filed multiple resale registration statements registering the resale of the shares of Common Stock issuable upon exercise of our outstanding warrants, each of which was declared effective by the SEC. The issuance of shares of Common Stock upon exercise of these warrants would dilute existing stockholders.
If we raise additional funds by issuing equity securities, our stockholders will experience dilution. Debt financing, if available, would result in increased fixed payment obligations and may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. Any debt financing or additional equity that we raise may contain terms, such as liquidation and other preferences, which are not favorable to us or our stockholders. If we raise additional funds through collaboration and licensing arrangements with third parties, it may be necessary to relinquish valuable rights to our technologies, future revenue streams, research programs or product candidates or to grant licenses on terms that may not be favorable to us. Should the financing we require to sustain our working capital needs be unavailable or prohibitively expensive when we require it, our business, operating results, financial condition and prospects could be materially and adversely affected, and we may be unable to continue our operations.
To the extent that we raise additional capital through a public or private offering and sale of equity securities, your ownership interest will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect your rights as a stockholder. Sales of our Common Stock offered through current or future equity offerings may result in substantial dilution to our stockholders. Sales of substantial amounts of our Common Stock in the public market, or the perception that such sales may occur, could adversely affect the market price of our Common Stock. The existence of a significant number of outstanding warrants may also make it more difficult for us to raise additional capital on favorable terms.
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.
| (a) | Unregistered Sales of Equity Securities |
We did not sell any equity securities during the quarter ended September 30, 2026 and up to the date of the filing of this Quarterly Report on Form 10-Q in transactions that were not registered under the Securities Act other than as previously disclosed in our filings with the SEC.
| (b) | Use of Proceeds |
Not applicable.
| (c) | Issuer Purchases of Equity Securities |
Not applicable.
32
Item 3. Defaults Upon Senior Securities.
Not applicable.
Item 4. Mine Safety Disclosures.
Not applicable.
Item 5. Other Information.
Disclosure of Material Event
The information set forth below is included herein for purposes of providing disclosures under Item 8.01 of Form 8-K.
On November 5, 2026, the Board acted under Section 204 of the Delaware General Corporation Law (the “DGCL”) to ratify certain potentially defective corporate acts related to sales of our Common Stock under the At The Market Offering Agreement, dated March 11, 2024 (the “Sales Agreement”), with H.C. Wainwright & Co., LLC, as sales agent (the “Ratification”). The Ratification is effective as of the original issuance time of each share. The Ratification does not require stockholder approval under Section 204, and no certificate of validation is required to be filed with the Delaware Secretary of State.
The statutory notice to the Company’s stockholders required by Section 204(g) of the DGCL is filed as Exhibit 99.1 to this Current Report on Form 8-K (the “Notice”) and is incorporated herein by reference. The Notice contains additional information about the ratified corporate acts and stockholders’ rights regarding the Ratification. This includes the requirement that any claim challenging the Ratification be brought within 120 days from the date of the Notice. This Current Report on Form 8-K, including the Notice, is intended to satisfy the notice requirements of Section 204(g) of the DGCL.
Insider Trading Arrangements
During the quarter ended September 30, 2026, no officer or director of the Company
Item 6. Exhibits.
| Exhibit No. | Description | |
| 3.1 | Amended and Restated Certificate of Incorporation (Incorporated by reference as Exhibit 3.3 to the Registration Statement on Form S-1 (File No. 333-267562) filed on September 22, 2022) | |
| 3.2 | Amended and Restated Bylaws (Incorporated by reference as Exhibit 3.2 to the Registration Statement on Form S-1 (File No. 333-267562) filed on December 6, 2022) | |
| 3.3 | Certificate of Amendment of the Amended and Restated Certificate of Incorporation of Cadrenal Therapeutics, Inc. (Incorporated by reference as Exhibit 3.1 to the Current Report on Form 8-K filed on August 20, 2024) | |
| 4.1 | Form of Pre-Funded Warrant (incorporated by reference as Exhibit 4.1 to the Current Report on Form 8-K filed on July 1, 2026) | |
| 4.2 | Form of Series C-1 Warrant (incorporated by reference as Exhibit 4.2 to the Current Report on Form 8-K filed on July 1, 2026) | |
| 4.3 | Form of Series C-2 Warrant (incorporated by reference as Exhibit 4.3 to the Current Report on Form 8-K filed on July 1, 2026) | |
| 4.4 | Form of Placement Agent Warrant (incorporated by reference as Exhibit 4.4 to the Current Report on Form 8-K filed on July 1, 2026) | |
| 10.1 | Form of Securities Purchase Agreement (incorporated by reference as Exhibit 10.1 to the Current Report on Form 8-K filed on July 1, 2026) | |
| 10.2 | Form of Registration Rights Agreement (incorporated by reference as Exhibit 10.2 to the Current Report on Form 8-K filed on July 1, 2026) | |
| 10.3# | Confidential Separation Agreement and General Release by and between Cadrenal Therapeutics, Inc. and James J. Ferguson III (incorporated by reference as Exhibit 10.1 to the Current Report on Form 8-K filed on July 17, 2026 | |
| 10.4# | Amendment No. 2 to the Cadrenal Therapeutics, Inc. 2022 Successor Equity Incentive Plan, dated September 24, 2026 (incorporated by reference as Exhibit 10.1 to the Current Report on Form 8-K filed on September 29, 2026) | |
| 31.1* | Certification of the Principal Executive Officer Pursuant to Rule 13a-14 and 15d-14 of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 | |
| 31.2* | Certification of the Principal Financial Officer and Principal Accounting Officer Pursuant to Rule 13a-14 and 15d-14 of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 | |
| 32.1* | Certification by the Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 | |
| 32.2* | Certification by the Principal Financial Officer and Principal Accounting Officer Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 | |
| 99.1* | Notice of Ratification Pursuant to Section 204(g) of the Delaware General Corporation Law | |
| 101.INS | Inline XBRL Instance* | |
| 101.SCH | Inline XBRL Taxonomy Extension Schema* | |
| 101.CAL | Inline XBRL Taxonomy Extension Calculation* | |
| 101.DEF | Inline XBRL Taxonomy Extension Definition* | |
| 101.LAB | Inline XBRL Taxonomy Extension *Label* | |
| 101.PRE | Inline XBRL Taxonomy Extension Presentation* | |
| 104 | Cover Page Interactive Data File (the cover page XBRL tags are embedded within the inline XBRL document) |
| * | Filed herewith. |
| # | Management contract or compensatory plan or arrangement. |
33
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| Cadrenal Therapeutics, Inc. | |
| (Registrant) | |
| Dated: November 16, 2026 | /s/ Quang X. Pham |
| Quang X. Pham | |
Chairman of the Board and Chief Executive Officer (Principal Executive Officer) |
| Dated: November 16, 2026 | /s/ John P. Sharp |
| John P. Sharp | |
| Interim Chief Financial Officer | |
| (Interim Principal Financial and Interim Accounting Officer) |
34